![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Klumpp Klaus
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.14, Iss.8, 2004-08, pp. : 1153-1168
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Preclinical Development of Low Toxicity Drugs: Focus on Zanamivir, an Anti-Influenza Drug
By Dines G.D.
Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. :